IDH2 and central nervous system cancer: They subsequently compared the expression levels of TRHDE-AS1 in different clinical types of glioma and found significant differences in pathological typing, WHO typing, molecular typing, IDH mutation, age stratification, etc., indicating that LncRNA-TRHDE-AS1 can serve as a potential biological marker for glioma diagnosis.